ArticleCancers2023

Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment.

Marco Carlo Merlano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.